Genmab — April 2021

[Bulder]

Nice E L. So if they can't pursue hexacd38 in MM, they have dr5/dr5 in stead.

[E_L]

very exciting!

[Darvin]

Thanks E L

[GeorgeBest]

Presume they can only use it for patients not on dara anymore? Probably only later lines of treatment?

[E_L]

you mean from a JNJ perspective?

[Darvin]

They write "cytotoxicity can be enhanced via combination with bortezomib, daratumumab, or lenalidomide"

[E_L]

I think they can use other drugs for MM, as long as it isn't
CD38

[GeorgeBest]

Yes okay, makes sence

[E_L]

i think it is funny how they write 'Daratumumab showed additive effects when combined with HexaBody-DR5/DR5' ; as in: the big multiple blockbuster could help a bit, instead of writing DR5 could help Dara a bit lol

[E_L]

but anyway, even more interested to see the first clinical data now in solids, to see if this isn't too toxic in human

[JørgenVarnæs]

GEN said update on DR5 during 2021 - and primary completion in dec21. Do we know anything more specific?

[kkjoel]

Was just about to ask the same
...

[Sukkeralf]

No

[JørgenVarnæs]

Asco er vel for tidligt? Er der en konference i efteråret, der passer?

[Sukkeralf]

ESMO er vel bedste bud - plejer at ligge i september

[Sukkeralf]

Det kan evt også blot være en opdatering hos Genmab selv - specielt hvis data er lidt mudrede

[JørgenVarnæs]

Lyder rigtigt

[StockBull]

mon ikke vi skal lidt op på den helt korte bane 5 min grafen indikere op på min skærm

[AaBforever]

Du må have en ny skærm:-D

[AaBforever]

Eller vende den på hovedet....